Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types

Conditions:   Sarcoma;   Ovarian Neoplasm;   Central Nervous System Neoplasm;   Thyroid Neoplasm;   Carcinoma, Neuroendocrine;   Neoplasms, Germ Cell and Embryonal
Intervention:   Drug: Pembrolizumab
Sponsors:   UNICANCER;   National Cancer Institute, France;   Ligue contre le cancer, France;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified January 2017

http://ift.tt/2i0fQes